USP Flags Gaps in the HHS Peptide Policy (Nov 2026)
On 3 Nov 2026, USP said the HHS peptide policy lacks key quality safeguards. Learn what a monograph and reference standard add to a COA.
Summary. The US Pharmacopeia (USP), the standards body behind the USP–NF quality monographs, said on 3 November 2026 that the peptide compounding policy the Department of Health and Human Services released the week before does not include essential safeguards to help ensure the quality of compounded preparations. USP says the peptide substances in the policy have no USP–NF monographs, no USP Reference Standards and no established official names, such as a United States Adopted Name or International Nonproprietary Name, that define their identity and substance-specific quality attributes. According to USP, its scientific review ahead of FDA's July 2026 advisory committee meeting found these substances not sufficiently characterized to support consistent evaluation of their quality, and without that identity and those standards, the quality of the bulk substance cannot be reliably and consistently established. USP adds that the general USP standards referenced in the policy cannot, on their own, provide adequate quality assurance. Our FDA Peptide Compounding Policy Tracker follows each step.
Research context (RUO). A monograph is a published specification for one named substance: the tests, methods and limits a batch must meet. A reference standard is a physical, characterized sample that a lab measures its own result against. When both exist, a certificate of analysis (COA) can be checked against a shared yardstick; when they do not, each lab sets its own methods and acceptance limits. USP says developing monographs would first need scientific information on identity and quality attributes and official names from the naming bodies. USP also says that no existing or new standard replaces a regulator's role in deciding whether a product is safe and effective. The HHS policy itself (FR Doc. 2026-22192) is a draft enforcement discretion policy that relies on a valid COA from an FDA-registered facility; comments are open on regulations.gov until 13 November 2026. Our COA page shows what a lot-level certificate contains, and the Academy chapter on basic terms explains the vocabulary. These rules concern compounding for patients, not research-grade material.
This summary is for research-community awareness only and is not legal advice. For research use only. Not for human or veterinary use.